Sarepta’s gene therapy for Duchenne muscular dystrophy (DMD ... on its earlier accelerated approval with a very narrow label covering ambulatory boys aged between four and five.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback